Patents by Inventor Laurent Magnenat

Laurent Magnenat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody with specificity for GM-CSF (II)
    Patent number: 9567398
    Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 14, 2017
    Assignee: MERCK SERONO S.A.
    Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
  • Antibody with specificity for GM-CSF (I)
    Patent number: 9567397
    Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 14, 2017
    Assignee: MERCK SERONO S.A.
    Inventors: Laurent Magnenat, Olivier Leger, Charles Mackay, David Georges Zahra
  • ANTIBODY WITH SPECIFICITY FOR GM-CSF (II)
    Publication number: 20140065163
    Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.
    Type: Application
    Filed: November 17, 2011
    Publication date: March 6, 2014
    Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
  • Soluble Il-17Rc Variant and Uses Thereof
    Publication number: 20080305078
    Abstract: The present invention relates to a new soluble IL-17RC variant and its therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders or neurological diseases.
    Type: Application
    Filed: December 22, 2006
    Publication date: December 11, 2008
    Applicant: LABORATOIRES SERONO SA
    Inventors: Laurent Magnenat, Christine Power